Pregene Biopharma
Shenzhen, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An innovative Chinese biotech developing CAR-T and CAR-NK cell therapies for oncology and autoimmune diseases with global commercialization ambitions.
OncologyImmunology
Technology Platform
Integrated platform for cellular drug R&D and industrialization, featuring nanobody screening, multi-gene editing (including iPSC reprogramming), and cell-directed differentiation technologies to develop CAR-T and CAR-NK therapies.
Opportunities
Global expansion through strategic out-licensing deals (e.g., India with Dr.
Reddy's) and leveraging its iPSC/gene-editing platforms to develop next-generation, off-the-shelf allogeneic cell therapies.
Risk Factors
Intense competition in the CAR-T space, particularly in hematological cancers; clinical and manufacturing challenges associated with solid tumor cell therapies and scaling production for global markets.
Competitive Landscape
Competes with global CAR-T leaders (e.g., Novartis, Gilead) and a crowded field of Chinese biotechs (e.g., JW Therapeutics, Gracell). Differentiates through its nanobody platform, multi-gene editing capabilities, and early success in securing international partnerships.